Patents Assigned to Blanchette Rockefeller Neuroscience Institute
-
Patent number: 9833435Abstract: The present disclosure is directed to compositions comprising bryostatin-1, and methods comprising administering a composition comprising bryostatin-1, to treat Niemann-Pick Type C in a subject in need thereof.Type: GrantFiled: March 27, 2015Date of Patent: December 5, 2017Assignee: Blanchette Rockefeller Neurosciences InstituteInventor: Daniel L. Alkon
-
Publication number: 20170319541Abstract: The present invention provides methods of slowing or reversing the loss of memory and learning comprising the steps of contacting an effective amount of a PKC activator with a protein kinase C (PKC) in a subject identified with memory loss slowing or reversing memory loss. The present invention provides methods of stimulating cellular growth, neuronal growth, dendritic growth, dendritic spine formation, dendritic spine density, and the translocation of ELAV to proximal dendrites, and synaptic remodeling. The present invention also provides methods of contacting a protein kinase C (PKC) activator with a PKC activator in a manner sufficient to stimulate the synthesis of proteins sufficient to consolidate long-term memory. The present invention also provides methods of contacting a protein kinase C (PKC) activator with a PKC activator in a manner sufficient to downregulate PKC.Type: ApplicationFiled: March 24, 2014Publication date: November 9, 2017Applicant: Blanchette Rockefeller Neuroscience InstituteInventor: Daniel L. ALKON
-
Patent number: 9446020Abstract: The present invention relates to compositions and methods to modulate ?-secretase and/or to improve cognitive ability. The invention further relates the improved/enhanced cognitive ability in diseased individuals, particularly Alzheimer's Disease patients, and treatment thereof through increased sAPP production. Macrocyclic lactones (i.e. bryostatin class and neristatin class) are compounds preferred for use with the present composition. The present invention also provides methods for increasing the generation of non-amyloidogenic soluble APP comprising the activation of protein kinase C (PKC) by administering an effective amount of PKC activator(s).Type: GrantFiled: November 2, 2015Date of Patent: September 20, 2016Assignee: Blanchette Rockefeller Neurosciences InstituteInventors: Rene Etcheberrigaray, Daniel L. Alkon
-
Patent number: 9345685Abstract: The present invention relates to compositions comprising a combination of PKC activators and PKC inhibitors and methods to modulate ?-secretase activity; improve or enhance cognitive ability; and or reduce neurodegeneration in individuals suffering from diseases that impair cognitive ability, particularly Alzheimer's Disease. The invention also relates to methods for improving or enhancing cognitive ability. The present invention also provides methods for increasing the generation of non-amyloidogenic soluble APP (sAPP) comprising the activation of protein kinase C (PKC) in the brain and inhibiting PKC in peripheral tissues. Macrocyclic lactones (i.e. bryostatin class and neristatin class) are preferred PKC activators and Vitamin E is a preferred PKC inhibitor for use in the inventive composition.Type: GrantFiled: September 16, 2010Date of Patent: May 24, 2016Assignee: Blanchette Rockefeller Neuroscience InstituteInventor: Daniel Alkon
-
Publication number: 20160074359Abstract: The present invention provides methods of slowing or reversing the loss of memory and learning comprising the steps of contacting an effective amount of a PKC activator with a protein kinase C (PKC) in a subject identified with memory loss slowing or reversing memory loss. The present invention provides methods of stimulating cellular growth, neuronal growth, dendritic growth, dendritic spine formation, dendritic spine density, and the translocation of ELAV to proximal dendrites, and synaptic remodeling. The present invention also provides methods of contacting a protein kinase C (PKC) activator with a PKC activator in a manner sufficient to stimulate the synthesis of proteins sufficient to consolidate long-term memory. The present invention also provides methods of contacting a protein kinase C (PKC) activator with a PKC activator in a manner sufficient to downregulate PKC.Type: ApplicationFiled: March 24, 2014Publication date: March 17, 2016Applicant: Blanchette Rockefeller Neuroscience InstituteInventor: Daniel L. ALKON
-
Publication number: 20160060236Abstract: The present invention relates to methods of activate an isoform of protein kinase C (PKC) for the treatment of neurological diseases including Alzheimer's disease and stroke using cyclopropanated or epoxidized derivatives of mono- and polyunsaturated fatty acids. The present invention also relates to methods of reducing neurodegeneration using cyclopropanated or epoxidized derivatives of mono- and polyunsaturated fatty acids.Type: ApplicationFiled: July 20, 2015Publication date: March 3, 2016Applicant: Blanchette Rockefeller Neurosciences InstituteInventors: Thomas J. NELSON, Daniel L. ALKON
-
Patent number: 9119825Abstract: The present invention relates to methods of activate an isoform of protein kinase C (PKC) for the treatment of neurological diseases including Alzheimer's disease and stroke using cyclopropanated or epoxidized derivatives of mono- and polyunsaturated fatty acids. The present invention also relates to methods of reducing neurodegeneration using cyclopropanated or epoxidized derivatives of mono- and polyunsaturated fatty acids.Type: GrantFiled: February 21, 2012Date of Patent: September 1, 2015Assignee: Blanchette Rockefeller Neurosciences InstituteInventors: Thomas J. Nelson, Daniel L. Alkon
-
Patent number: 9107890Abstract: The present disclosure provides a method for treating stroke by administering to a subject an anticoagulant, e.g., recombinant tissue plasminogen activator (rTPA), and a protein kinase C (PKC) activator followed by administration of at least one PKC activator for a duration of treatment. The methods disclosed herein may limit the size of infarction and/or reduce mortality, the disruption of the blood-brain barrier, and/or the hemorrhagic damage due to ischemic stroke compared with rTPA administration alone; and may also extend the therapeutic time window for administering rTPA after a stroke. Also disclosed are kits comprising rTPA and a PKC activator for treating stroke.Type: GrantFiled: July 8, 2011Date of Patent: August 18, 2015Assignee: Blanchette Rockefeller Neurosciences InstituteInventor: Daniel L. Alkon
-
Patent number: 9066923Abstract: The present invention relates to compositions comprising a combination of PKC activators and PKC inhibitors and methods to modulate ?-secretase activity; improve or enhance cognitive ability; and/or reduce neurodegeneration in individuals suffering from diseases that impair cognitive ability, particularly Alzheimer's Disease. The invention also relates to methods for improving or enhancing cognitive ability. The present invention also provides methods for increasing the generation of non-amyloidogenic soluble APP (sAPP) comprising the activation of protein kinase C (PKC) in the brain and inhibiting PKC in peripheral tissues. Macrocyclic lactones (i.e. bryostatin class and neristatin class) are preferred PKC activators and Vitamin E is a preferred PKC inhibitor for use in the inventive composition.Type: GrantFiled: August 10, 2009Date of Patent: June 30, 2015Assignee: Blanchette Rockefeller Neurosciences InstituteInventor: Daniel Alkon
-
Publication number: 20140329264Abstract: Methods of diagnosing Alzheimer's disease are provided. At least five methods of diagnostic measurements are presented: Method 1: Integrated score; Method 2: Average aggregate area per number of aggregates; Method 3: Cell migration analysis; Method 4: Fractal analysis; Method 5: Lacunarity Analysis. In certain embodiments, a sample of a subject's skin provides a network of fibroblasts that is imaged and a fractal dimension of the image is calculated. The fractal dimension can be compared to an aged-matched control (non-Alzheimer's) database to determine if the subject has Alzheimer's disease. The network of fibroblasts may be cultured in a matrix, for example in a protein mixture.Type: ApplicationFiled: February 10, 2014Publication date: November 6, 2014Applicant: Blanchette Rockefeller Neurosciences InstituteInventors: Florin Valentin CHIRILA, Tapan Kumar Khan, Daniel L. Alkon
-
Publication number: 20140248648Abstract: The present disclosure relates to a peripheral diagnostic method for screening Alzheimer's disease in patients based on quantitatively measured complexity of skin-sampled fibroblast networks.Type: ApplicationFiled: May 11, 2012Publication date: September 4, 2014Applicant: Blanchette Rockefeller Neurosciences InstituteInventors: Florin V. Chirila, Tapan Kumar Khan, Daniel L. Alkon
-
Publication number: 20140249176Abstract: The present invention provides methods of contacting a protein kinase C (PKC) activator with a PKC activator in a manner sufficient to stimulate the synthesis of proteins sufficient to consolidate long-term memory. The present invention also provides methods of contacting a protein kinase C (PKC) activator with a PKC activator in a manner sufficient to downregulate PKC.Type: ApplicationFiled: March 4, 2014Publication date: September 4, 2014Applicant: Blanchette Rockefeller Neurosciences InstituteInventor: Daniel L. Alkon
-
Patent number: 8822166Abstract: The present invention relates to a method for diagnosing Alzheimer's Disease (AD) using PKC-elicited gene expression profiles. PKC-activation elicits different genomic profiles in AD cells, as compared with control cells, which can be used to diagnose AD and individuals at risk for developing AD.Type: GrantFiled: July 28, 2009Date of Patent: September 2, 2014Assignee: Blanchette Rockefeller Neurosciences InstituteInventors: Daniel L. Alkon, Tapan Kumar Khan
-
Patent number: 8703812Abstract: The present invention provides methods of contacting a protein kinase C (PKC) activator with a PKC activator in a manner sufficient to stimulate the synthesis of proteins sufficient to consolidate long-term memory. The present invention also provides methods of contacting a protein kinase C (PKC) activator with a PKC activator in a manner sufficient to downregulate PKC.Type: GrantFiled: July 30, 2012Date of Patent: April 22, 2014Assignee: Blanchette Rockefeller Neurosciences InstituteInventor: Daniel L. Alkon
-
Patent number: 8658134Abstract: Methods of diagnosing Alzheimer's disease are provided. At least five methods of diagnostic measurements are presented: Method 1: Integrated score; Method 2: Average aggregate area per number of aggregates; Method 3: Cell migration analysis; Method 4; Fractal analysis; Method 5: Lacunarity Analysis. In certain embodiments, a sample of a subject's skin provides a network of fibroblasts that is imaged and a fractal dimension of the image is calculated. The fractal dimension can be compared to an aged-matched control (non-Alzheimer's) database to determine if the subject has Alzheimer's disease. The network of fibroblasts may be cultured in a matrix, for example in a protein mixture.Type: GrantFiled: October 2, 2010Date of Patent: February 25, 2014Assignee: Blanchette Rockefeller Neurosciences InstituteInventors: Florin Valentin Chirila, Tapan Kumar Khan, Daniel L. Alkon
-
Publication number: 20140031245Abstract: The present invention relates to methods of diagnosing Alzheimer's Disease as well as to methods of confirming the presence or absence of Alzheimer's Disease in a subject. The present invention is also directed to methods of identifying a lead compound useful for the treatment of Alzheimer's Disease by contacting non-Alzheimers cells with an amyloid beta peptide, stimulating the cells with a protein kinase C activator, contacting the cells with a test compound, and determining the value of an Alzheimer's Disease-specific molecular biomarker. The present invention is also directed to methods of diagnosing Alzheimer's Disease in a subject by detecting alterations in the ratio of specific phosphorylated MAP kinase proteins in cells after stimulation with a protein kinase C activator.Type: ApplicationFiled: February 22, 2013Publication date: January 30, 2014Applicant: BLANCHETTE ROCKEFELLER NEUROSCIENCES INSTITUTEInventor: BLANCHETTE ROCKEFELLER NEUROSCIENCE INSTITUTE
-
Publication number: 20130331427Abstract: The present invention provides methods of slowing or reversing the loss of memory and learning comprising the steps of contacting an effective amount of a PKC activator with a protein kinase C (PKC) in a subject identified with memory loss slowing or reversing memory loss. The present invention provides methods of stimulating cellular growth, neuronal growth, dendritic growth, dendritic spine formation, dendritic spine density, and the translocation of ELAV to proximal dendrites, and synaptic remodeling. The present invention also provides methods of contacting a protein kinase C (PKC) activator with a PKC activator in a manner sufficient to stimulate the synthesis of proteins sufficient to consolidate long-term memory. The present invention also provides methods of contacting a protein kinase C (PKC) activator with a PKC activator in a manner sufficient to downregulate PKC.Type: ApplicationFiled: October 25, 2012Publication date: December 12, 2013Applicant: Blanchette Rockefeller Neuroscience InstituteInventor: Blanchette Rockefeller Neuroscience Institute
-
Publication number: 20130331444Abstract: The present disclosure provides methods of treating a cognitive disorder associated with abnormal dendritic spines, such as Fragile X Syndrome, Fragile X Associated Tremor/Ataxia Syndrome, autism, or mental retardation, using PKC activators.Type: ApplicationFiled: August 19, 2011Publication date: December 12, 2013Applicant: BLANCHETTE ROCKEFELLER NEUROSCIENCES INSTITUTEInventors: Miao-kun Sun, Daniel L. Alkon
-
Publication number: 20130231384Abstract: The present invention provides methods of slowing or reversing the loss of memory and learning comprising the steps of contacting an effective amount of a PKC activator with a protein kinase C (PKC) in a subject identified with memory loss slowing or reversing memory loss. The present invention provides methods of stimulating cellular growth, neuronal growth, dendritic growth, dendritic spine formation, dendritic spine density, and the translocation of ELAV to proximal dendrites, and synaptic remodeling. The present invention also provides methods of contacting a protein kinase C (PKC) activator with a PKC activator in a manner sufficient to stimulate the synthesis of proteins sufficient to consolidate long-term memory. The present invention also provides methods of contacting a protein kinase C (PKC) activator with a PKC activator in a manner sufficient to downregulate PKC.Type: ApplicationFiled: September 27, 2012Publication date: September 5, 2013Applicant: BLANCHETTE ROCKEFELLER NEUROSCIENCE INSTITUTEInventor: Daniel L. Alkon
-
Publication number: 20130165375Abstract: The invention provides for the use of carbonic anhydrase activators; protein kinase C activators and FGF-18 to treat depressive disorders. The invention also relates to improved animal models and methods for screening and identifying compounds to treat depressive disorders.Type: ApplicationFiled: November 5, 2012Publication date: June 27, 2013Applicant: Blanchette Rockefeller Neuroscience InstituteInventor: Blanchette Rockefeller Neuroscience Institute